A Dose-Response Safety Study of ENX-102 in Patients With GAD

NCT06653296 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

General Anxiety Disorder

Interventions

DRUG: ENX-102
DRUG: Placebo

Sponsor

Engrail Therapeutics INC